{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:50:14Z","timestamp":1790959814925,"version":"4.1.0"},"reference-count":60,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872176"],"award-info":[{"award-number":["81872176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902735"],"award-info":[{"award-number":["81902735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072973"],"award-info":[{"award-number":["82072973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Basic and Applied Basic Research Foundation of Guang-dong province","award":["2019A1515010342"],"award-info":[{"award-number":["2019A1515010342"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The molecular characteristics of prostate cancer (PCa) cells and the immunosuppressive bone tumor microenvironment (TME) contribute to the limitations of immune checkpoint therapy (ICT). Identifying subgroups of patients with PCa for ICT remains a challenge. Herein, we report that basic helix-loop-helix family member e22 (BHLHE22) is upregulated in bone metastatic PCa and drives an immunosuppressive bone TME.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, the function of BHLHE22 in PCa bone metastases was clarified. We performed immunohistochemical (IHC) staining of primary and bone metastatic PCa samples, and assessed the ability to promote bone metastasis in vivo and in vitro. Then, the role of BHLHE22 in bone TME was determined by immunofluorescence (IF), flow cytometry, and bioinformatic analyses. RNA sequencing, cytokine array, western blotting, IF, IHC, and flow cytometry were used to identify the key mediators. Subsequently, the role of BHLHE22 in gene regulation was confirmed using luciferase reporter, chromatin immunoprecipitation assay, DNA pulldown, co-immunoprecipitation, and animal experiments. Xenograft bone metastasis mouse models were used to assess whether the strategy of immunosuppressive neutrophils and monocytes neutralization by targeting protein arginine methyltransferase 5 (PRMT5)\/colony stimulating factor 2 (CSF2) could improve the efficacy of ICT. Animals were randomly assigned to treatment or control groups. Moreover, we performed IHC and correlation analyses to identify whether BHLHE22 could act as a potential biomarker for ICT combination therapies in bone metastatic PCa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tumorous BHLHE22 mediates the high expression of CSF2, resulting in the infiltration of immunosuppressive neutrophils and monocytes and a prolonged immunocompromised T-cell status. Mechanistically, BHLHE22 binds to the <jats:italic>CSF2<\/jats:italic> promoter and recruits PRMT5, forming a transcriptional complex. PRMT5 epigenetically activates <jats:italic>CSF2<\/jats:italic> expression. In a tumor-bearing mouse model, ICT resistance of Bhlhe22<jats:sup>+<\/jats:sup> tumors could be overcome by inhibition of Csf2 and Prmt5.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results reveal the immunosuppressive mechanism of tumorous BHLHE22 and provide a potential ICT combination therapy for patients with BHLHE22<jats:sup>+<\/jats:sup> PCa.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005532","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T11:15:56Z","timestamp":1679310956000},"page":"e005532","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01057810","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03016312","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chi","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pathology, the First People\u2019s Hospital of Guangzhou City, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuandong","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhu","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-3703","authenticated-orcid":false,"given":"Xinsheng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China"},{"name":"Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"2025100304414603000_11.3.e005532.1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025100304414603000_11.3.e005532.2","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10126","article-title":"Bone as a preferential site for metastasis","volume":"3","author":"Sowder","year":"2019","journal-title":"JBMR Plus"},{"key":"2025100304414603000_11.3.e005532.3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180661"},{"key":"2025100304414603000_11.3.e005532.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.44"},{"key":"2025100304414603000_11.3.e005532.5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2025100304414603000_11.3.e005532.6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100304414603000_11.3.e005532.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7270"},{"key":"2025100304414603000_11.3.e005532.8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051517-011947"},{"key":"2025100304414603000_11.3.e005532.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3055"},{"key":"2025100304414603000_11.3.e005532.10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s43018-020-00141-0","article-title":"Accelerating precision medicine in metastatic prostate cancer","volume":"1","author":"Mateo","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100304414603000_11.3.e005532.11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrell","year":"2015","journal-title":"Eur Urol"},{"key":"2025100304414603000_11.3.e005532.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7421"},{"key":"2025100304414603000_11.3.e005532.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100304414603000_11.3.e005532.14","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2021.09.004","article-title":"A rare insight into the immunosuppressive landscape of prostate cancer bone metastases","volume":"39","author":"Palena","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100304414603000_11.3.e005532.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"2025100304414603000_11.3.e005532.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"2025100304414603000_11.3.e005532.17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"2025100304414603000_11.3.e005532.18","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.2.626"},{"key":"2025100304414603000_11.3.e005532.19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","article-title":"The placental gene PEG10 promotes progression of neuroendocrine prostate cancer","volume":"12","author":"Akamatsu","year":"2015","journal-title":"Cell Rep"},{"key":"2025100304414603000_11.3.e005532.20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"2025100304414603000_11.3.e005532.21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"2025100304414603000_11.3.e005532.22","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49"},{"key":"2025100304414603000_11.3.e005532.23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jbmr.5650010210","article-title":"Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures","volume":"1","author":"MacDonald","year":"1986","journal-title":"J Bone Miner Res"},{"key":"2025100304414603000_11.3.e005532.24","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx1188","article-title":"JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework","volume":"46","author":"Khan","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2025100304414603000_11.3.e005532.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.009"},{"key":"2025100304414603000_11.3.e005532.26","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2002.6833"},{"key":"2025100304414603000_11.3.e005532.27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41417-021-00327-3","article-title":"Prmt5: a putative oncogene and therapeutic target in prostate cancer","volume":"29","author":"Beketova","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"2025100304414603000_11.3.e005532.28","doi-asserted-by":"publisher","DOI":"10.15698\/cst2020.08.228"},{"key":"2025100304414603000_11.3.e005532.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.029"},{"key":"2025100304414603000_11.3.e005532.30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180749"},{"key":"2025100304414603000_11.3.e005532.31","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1038\/s41418-019-0302-0","article-title":"Sting signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ"},{"key":"2025100304414603000_11.3.e005532.32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"Prmt5 control of cgas\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100304414603000_11.3.e005532.33","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.287"},{"key":"2025100304414603000_11.3.e005532.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8"},{"key":"2025100304414603000_11.3.e005532.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.06.009"},{"key":"2025100304414603000_11.3.e005532.36","doi-asserted-by":"publisher","DOI":"10.1038\/nature21676"},{"key":"2025100304414603000_11.3.e005532.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4773(02)00036-9"},{"key":"2025100304414603000_11.3.e005532.38","doi-asserted-by":"publisher","DOI":"10.1242\/dev.057281"},{"key":"2025100304414603000_11.3.e005532.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.09.035"},{"key":"2025100304414603000_11.3.e005532.40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13402-020-00577-7","article-title":"Protein arginine methyltransferase 5: a potential cancer therapeutic target","volume":"44","author":"Yuan","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"2025100304414603000_11.3.e005532.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1228"},{"key":"2025100304414603000_11.3.e005532.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.028"},{"key":"2025100304414603000_11.3.e005532.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"2025100304414603000_11.3.e005532.44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2019.03.020","article-title":"Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer","volume":"76","author":"Chen","year":"2019","journal-title":"Eur Urol"},{"key":"2025100304414603000_11.3.e005532.45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","article-title":"Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer","volume":"77","author":"Isaacsson Velho","year":"2020","journal-title":"Eur Urol"},{"key":"2025100304414603000_11.3.e005532.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3677"},{"key":"2025100304414603000_11.3.e005532.47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2025100304414603000_11.3.e005532.48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100304414603000_11.3.e005532.49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","article-title":"Mdsc; the most important cell you have never heard of","volume":"40","author":"Tesi","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"2025100304414603000_11.3.e005532.50","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939903"},{"key":"2025100304414603000_11.3.e005532.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004"},{"key":"2025100304414603000_11.3.e005532.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0022-x"},{"key":"2025100304414603000_11.3.e005532.53","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3RU0316-144R"},{"key":"2025100304414603000_11.3.e005532.54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006858"},{"key":"2025100304414603000_11.3.e005532.55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5387","article-title":"Blocking immunosuppressive neutrophils deters py696-EZH2-driven brain metastases","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100304414603000_11.3.e005532.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.008"},{"key":"2025100304414603000_11.3.e005532.57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1352"},{"key":"2025100304414603000_11.3.e005532.58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27833-0","article-title":"Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-pi3k\u03b1\/\u03b2\/\u03b4 treatment","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"2025100304414603000_11.3.e005532.59","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00090-14"},{"key":"2025100304414603000_11.3.e005532.60","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0224"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:41:57Z","timestamp":1759491717000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/jitc-2022-005532"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005532","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}